AAV2-hCHM Subretinal Delivery to the Macula in Choroideremia: 2 year Results of an Ongoing Phase I/II Gene Therapy Trial
Tomás S. Alemán(Children's Hospital of Philadelphia), Albert M. Maguire(Children's Hospital of Philadelphia), Jason Comander(Massachusetts Eye and Ear Infirmary), Rachel M. Huckfeldt(Penn Presbyterian Medical Center), Dean Eliott(Massachusetts Eye and Ear Infirmary), Sarah McCague(Children's Hospital of Philadelphia), Eric A. Pierce(Broad Institute), Jean Bennett(Penn Presbyterian Medical Center), Grace K. Vergilio(Penn Presbyterian Medical Center), Denise J. Pearson(Penn Presbyterian Medical Center), Katherine E. Uyhazi(Penn Presbyterian Medical Center), Daniel C. Chung(Penn Presbyterian Medical Center), Kathleen Marshall(Children's Hospital of Philadelphia), Emily Liu(University of Iowa), Jessica Ijams Wolfing Morgan(Penn Presbyterian Medical Center), Leona Serrano(Penn Presbyterian Medical Center)
Investigative Ophthalmology & Visual Science
July 22, 2019
Cited by 7
Related Papers
Safety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis
|New England Journal of Medicine|2008|2.1k
Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins.
|Proceedings of the National Academy of Sciences|1995|1.3k
Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization.
|Proceedings of the National Academy of Sciences|1995|1k